echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Prediction of the list of products to be negotiated in 2019 national medical insurance catalogue

    Prediction of the list of products to be negotiated in 2019 national medical insurance catalogue

    • Last Update: 2019-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    One week after the release of 2019 national health insurance catalog, the noise brought by various data analysis and comment articles gradually calmed down The biggest egg should be the list of 128 negotiated varieties that have not yet been made public Today, let's guess with you Our principle is "just guess, don't include right, guess wrong also don't compensate" First of all, list several official clues about the varieties to be negotiated: the state health insurance bureau will negotiate the drugs to be negotiated according to the relevant procedures determined by the expert review, and the agreed drugs will be included in the payment scope of the health insurance fund The specific list and relevant requirements will be issued separately On the basis of summing up the previous experience, this catalogue adjustment has further improved the method of negotiation access For the patent exclusive drugs with high clinical value but high price or great influence on the fund, 128 drugs are preliminarily determined to be included in the scope of access to the proposed negotiation, including 109 western drugs and 19 Chinese patent drugs through expert review and voting These drugs are mainly used to treat cancer, rare diseases and other major diseases, hepatitis C, hepatitis B, hypertension, diabetes and other chronic diseases Many products are new drugs approved by SFDA in recent years, including major innovative drugs in China As there are many varieties in this negotiation and it generally has a great impact on the fund, there is no requirement for the success rate in this negotiation Because the negotiated varieties are mainly for exclusive or patent period protected high-priced varieties, we first select the exclusive varieties (or dosage forms) that are not in the national medical insurance catalog in the past years from pharmago database of medicine magic cube, narrow the target range, and then infer the list of varieties to be negotiated based on the above clues As shown in the table below, a total of 106 Western medicines and 10 Chinese patent medicines are provided Source: medicine cube
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.